The United States President Donald Trump has hit global pharmaceutical markets with a jolt, announcing a 100% tariff on all imported branded and patented pharmaceutical drugs. The order, revealed on Thursday, requires companies to ensure US-based manufacturing plants to avoid these steep import duties.

President Trump said: “I’m putting a 100% import tax on pharmaceutical drugs unless the companies are building plants right here in the United States. Breaking ground, under construction, that’s the deal. No exceptions”. This decision is a major push by the US administration to boost domestic manufacturing and reduce reliance on foreign suppliers.

Implications for Indian Pharma

The full force of Trump’s order falls on branded and patented drugs, a category where India’s contribution to the US pharma basket is limited. India exports more than a third of the drugs consumed in America, but the overwhelming majority are generic medicines — products that are no longer under patent and typically far cheaper than their branded rivals. According to most industry experts, this difference offers Indian pharmaceutical exporters a buffer, at least for now.

Dr. VK Vijayakumar, Chief Investment Strategist at Geojit Investments, commented that India, being a key exporter of generic medicines, should escape a direct hit in the immediate term. However, he cautioned that such a dramatic move could rattle market confidence and affect the sentiment of investors looking at the sector. He warned that there’s always a risk future tariff actions could expand to include generics, which would mark a significant challenge for Indian pharma.

Kranthi Bathini, Director of Equity Strategy at WealthMills Securities, shared a similar view. She said that while most of India’s drug exports to the US are non-branded or discretionary, any potential US tariff on critical medicines could result in higher healthcare costs and put pressure on profit margins. She believes a wait-and-watch approach is prudent until further clarity emerges about the specifics of the policy’s implementation.

Rahul Ahluwalia, Founder-Director of the Foundation for Economic Development, suggested that although India’s primary export segment remains unaffected at present, the aggressive move signals a warning for the sector’s future. He advocated for India to double its efforts to secure trade agreements with major markets such as the US and EU to protect the industry’s access and growth.

Market Reactions

The US market is the largest for Indian pharmaceuticals, accounting for roughly 35% of exports with an estimated value of USD 10 billion in FY25, according to Pharmaceuticals Export Promotion Council of India data. Brokerage firm Choice Institutional Equities noted that, while the tariffs are aimed at branded and patented medicines for now, there remains uncertainty about whether complex generics or specialty medicines could also be caught in the net. The exemption for firms with ongoing or recently begun US manufacturing projects may provide a limited window to hedge against tariff risks. Still, not all exporters will be able to pivot quickly enough to benefit.

The Trump administration’s shift from country-based to product-specific tariff policies hints at a tougher stance and a possible extension to other sectors in the near future. The current focus on branded drugs fits within a larger effort to protect domestic industry and reduce the trade deficit, with similar tariff actions seen in other product categories recently.

The announcement led to a knee-jerk reaction among Indian investors, particularly in the pharma sector. On Dalal Street, the Nifty Pharma index slid nearly 2% following the news, with heavyweight stocks such as Sun Pharma, Cipla, and Dr. Reddy’s experiencing sharp declines in the early hours of trade. Market participants attributed the sell-off not to direct business loss, but to fears over what such protectionist policies might signal for the future.

Investor Outlook and Sector Sentiment

Experts point out that the market’s reaction is more about sentiment than about any immediate threat to revenues from US-bound exports. Dr. Vijayakumar stressed that the bulk of US pharmaceutical imports from India are generics, so there is no direct and immediate business risk as per the current policy’s scope. However, he advised investors and companies to keep a close watch on further measures that might broaden the US tariff net to include generic medicines.

As it stands, the impact on India’s pharmaceutical export earnings may remain muted, but the episode lays bare the sector’s exposure to global policy volatility. The US has repeatedly emphasised its intent to lower reliance on foreign producers, particularly for critical sectors such as pharmaceuticals. In this context, the next few weeks will be crucial as Indian exporters, investors, and policymakers track how these tariffs are enforced and if any additional protectionist steps are announced.

The uncertainty also underlines the need for India’s pharma industry to deepen collaborations overseas and invest in higher-value segments, including drug innovation and specialty medicines, to stay resilient in the face of global headwinds.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share